The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

Evrysdi is the only non-invasive disease-modifying ... Calif., February 12, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and ...

The first prenatal therapy for spinal muscular atrophy (SMA) showed promising results, a case report indicated. More than 2 ...

Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month. Magargee has been serving ...

At close: February 17 at 5:31:07 PM GMT+1 ...

Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and commercialization of its advanced pharmaceutical technologies.